Additional Study Information: The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and is the current standard of care for CMV disease prevention in kidney transplant recipients. The study will last for approximately one year (52 weeks). Study treatment will start within seven days post-transplant and continue through 28 weeks. In total, subjects will be monitored for CMV disease for approximately a year after transplant.